Atlas Trials

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Clinical trial NCT06041620 · UNKNOWN

Trial details

NCT number
NCT06041620
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Thalassemia, BetaThalassemia Major
Start date
2023-08-31
Primary completion
2025-12-31
Enrollment
2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.